Boundless Bio Inc. is a biotechnology company at the forefront of developing novel therapies for oncogenic amplification in cancer treatment. The primary focus of the company is on the creation of precision medicines that target extrachromosomal DNA (ecDNA), which plays a crucial role in cancer progression and resistance to existing therapies. By pioneering research in this area, Boundless Bio aims to address significant unmet needs in oncogenic amplification-driven cancers, opening pathways for more effective treatment regimens. Boundless Bio operates in the life sciences sector, specifically impacting areas related to genetic research and cancer therapeutics. Its innovations are not only driving forward the understanding of cancer biology but are also crucial in developing targeted solutions that could significantly improve patient outcomes. With its groundbreaking approach, Boundless Bio holds a strategic position in the biotechnology market, contributing to the advancement of precision medicine. The company's work underscores a vital shift towards more personalized cancer treatments, highlighting the potential impact of genomic research in transforming healthcare and offering hope to patients with limited treatment options.